Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, PK and PD of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With T2DM Who Are Inadequately Controlled With Diet and Exercise or Diet, Exercise and Metformin
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Oramed Pharmaceuticals
- 30 Jan 2014 All primary (safety and tolerability) and secondary endpoints were met in the trial according to an Oramed Pharmaceuticals media release.
- 12 Nov 2013 Status changed from recruiting to completed, as reported by an Oramed Pharmaceuticals media release.
- 08 Jul 2013 Status changed from not yet recruiting to recruiting, according to an Oramed Pharmaceuticals media release. The first patient has been enrolled in this substudy.